This antibody reacts to BH3-interacting domain death agonist. It is expected to recognise all three reported isoforms (as represented by NP_932070.1, NP_001187.1, NP_932071.1)
Kreuzreaktivität (Details)
Species reactivity (tested):Human.
Aufreinigung
Affinity Chromatography
Immunogen
Peptide with sequence from the C Terminus of the protein sequence according to NP_932070.1, NP_001187.1, NP_932071.1. Genename: BID
Peptide ELISA: 1/8000. Western Blot: 0.1 - 0.3 μg/mL. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Konzentration
0.5 mg/mL
Buffer
Tris saline, pH ~7.3 containing 0.02 % Sodium Azide and 0.5 % BSA
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handhabung
Avoid repeated freezing and thawing.
Lagerung
4 °C/-20 °C
Informationen zur Lagerung
Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
Bid, a BH3 domain containing proapoptotic Bcl2 family member, is localized in the cytosolic fraction of cells as an inactive precursor. Its active form is generated upon proteolytic cleavage by caspase 8 in the Fas signaling pathway. Cleaved Bid translocates to mitochondria and releases its potent proapoptotic activity, which in turn induces cytochrome c release and mitochondrial damage. The cytochrome c releasing activity of Bid was antagonized by Bcl2. Mutation in the SH3 domain can diminish the cytochrome c releasing activity. In animal model studies, Bid deficient mice are found resistant to the lethal effects of death factor signals relayed through Fas.Synonyms: BH3-interacting domain death agonist, p22 BID